NCT02572778Recruiting
Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer
Establishment of Primary Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer for Preclinical Evaluation of Targeted Therapies.
Source: ClinicalTrials.gov · Last updated 3 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The investigators want to have a collection of fresh primary or recurrent tumor tissue for establishment of patients-derived xenografts in order to: generate a biobank of in vivo patient xenografts representing the different subgroups of tumors for head and neck cancer * perform genetic and transcriptional profiling of the primary, metastatic tumors and xenograft tumors * evaluate the efficacy of new targeted agents, whether or not in combination with standard treatment options * evaluate biomarkers of drug sensitivity * study primary and secondary (acquired) resistance in these models
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 40 (estimated)
- First submitted
- 22 Sept 2015
- Start date
- Sept 2015
- Primary completion date
- Dec 2025
- Lead sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Diseases
- Head and neck cancer
- NCT number
- NCT02572778
What you commit to
- Study type: Observational
- Planned participants: 40
- From Sept 2015 to the primary completion date, Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- In the first phase, all patients with primary or recurrent/ metastatic disease of head and neck cancer can be included pre-operatively or before a tumor biopsy after obtaining informed consent
- Data on stage, grade, histology, adjuvant treatment, responses, relapse should be available
- Follow-up data should be available
- Patients with recurrent disease are allowed
- Written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cliniques universitaires Saint-Luc Coordinator of this site? Confirm its status | Brussels | Belgium | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.